Markers of inflammation and risk of ovarian cancer in Los Angeles county

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1409-1415

  Wu, Anna H ^a,b   Pearce, Celeste L ^a   Tseng, Chiu Chen ^a   Templeman, Claire ^a   Pike, Malcolm C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Endometriosis; Non steroidal anti inflammatory drugs; Ovarian cancer; Talc

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; ACETYLSALICYLIC ACID PLUS CODEINE; ANACIN; APC; BIOLOGICAL MARKER; CELECOXIB; COCODAMOL; CODEINE; CORICIDIN; DEXTROPROPOXYPHENE; DRISTAN; EXCEDRIN; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PERCOCET; PERCOCET 5; PERCODAN; PIROXICAM; ROFECOXIB; SULINDAC; TALC; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UTILIZATION; ENDOMETRIOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UNITED STATES; ANAMNESIS; BLOOD; CONFIDENCE INTERVAL; EDUCATIONAL STATUS; ETHNIC GROUP; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; RACE; RISK; STATISTICS; UTERINE TUBE STERILIZATION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CONFIDENCE INTERVALS; CONTINENTAL POPULATION GROUPS; EDUCATIONAL STATUS; ENDOMETRIOSIS; ETHNIC GROUPS; FEMALE; HUMANS; INFLAMMATION; LOS ANGELES; MEDICAL HISTORY TAKING; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; RISK; STERILIZATION, TUBAL;

EID: 60549089851     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24091     Document Type: Article

References (29)

1. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-67.
2. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122:170-6.
3. Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL. Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol 2008;167:1430-7.
4. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapv and endometrial cancer. J Natl Cancer Inst 1997; 89:1110-16.
5. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-17.
6. Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis," Br J Clin Pharmacol 2005;60:194-203.
7. Cramer DW, Harlow BL, Titus-Emstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998:351:104-7.
8. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Francesehi S. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2000; 11:1171-3.
9. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002;22:303-9.
10. Rodriguez C, Henley SJ, Calle EE, Thun MJ. Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA, Lancet 1998:352:1354-5.
11. Friis S, Sorensen HT, McLaughlin IK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003;88:684-8.
12. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study, Br J Cancer 2003;88:1687-92.
13. Lacey JV, Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 2004;108:281-6.
14. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:903-6.
15. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002;13:535-42.
16. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:933-7.
17. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology 2006;17:104-7.
18. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 2008:98:1781-3.
19. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL. Shore RE. Aspirin and epithelial ovarian cancer, Prev Med 2001;33:682-7.
20. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999;81:542-8.
21. Olson JE, Cerhan JR, Janney CA, Anderson KE, Vachon CM, Sellers TA. Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa Women's Health Study. Cancer 2002;94:1612-18.
22. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer In women with and without endometriosis. Am J Obstet Gynecol 2004;191:733-40.
23. Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjaer SK, Graubard BI, Olsen JH, Mellemkjaer L. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev 2005; 14:2929-35.
24. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Cogliano V. Carcinogenicity of carbon black, titanium dioxide, and talc. Lancet Oncol 2006;7:295-6.
25. Cook LS, Kamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 1997; 145:459-65.
26. Cramer DW. Perineal talc exposure and subsequent epithelial ovarian cancer: a case-control study. Obstet Gynecol 1999;94:160-1.
27. Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol 1992;80:19-26.
28. Mills PK. Riordan DG, Cress RD, Young HA. Perineal talc exposure and epithelial ovarian cancer risk in the central valley of California. Int J Cancer 2004; 112:458-64.
29. Cramer DW, Liberman RF, Titus-Ernstoff L, Welch WR, Greenberg ER, Baron JA, Harlow BL. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999;81:351-6.